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Is cytisine contraindicated in smoking patients with coronary 
artery disease after percutaneous coronary intervention?
Bogumił Ramotowski, Andrzej Budaj
Department of Cardiology, Centre of Postgraduate Medical Education, Warszawa, Poland 
A B S T R A C T
Background: Cytisine is contraindicated, and its effects have not been evaluated in patients with 
coronary artery disease (CAD). 
Aims: The safety, feasibility, and short-term efficacy of cytisine for smoking cessation were evaluated 
in active smokers with CAD after percutaneous coronary interventions (PCI).
Methods: Patients with stable CAD and acute coronary syndromes (ACS), who smoked at least 10 cig-
arettes per day, were included 30 days post PCI and offered cytisine therapy. Adverse events, smoking 
activity, and drug adherence were assessed after 30 days.
Results: 117 patients participated (mean standard deviation [SD] age, 60.8 [7.7] years; men, 73.6%, 
median and interquartile range [IQR] of the number of pack-years, 40 [30–46.5]). Overall, 79 patients 
consented (study group) and 38 declined (control group) to use cytisine. At the follow-up visit, the 
incidence of adverse events did not differ between groups (17.7% vs 21%; P = 0.67). The groups had 
a similar success rate of smoking cessation in the intention-to-treat analysis (41.8% vs 36.8%; P = 0.61). 
In the as-treated analysis, patients who completed the therapy achieved a higher success rate than 
those who declined (69.7% vs 36.9%; P = 0.006) or did not complete therapy (69.7% vs 34.8%; P = 0.01). 
In the multivariable analysis, complete cytisine therapy and ACS at admission were associated with an 
increased and male sex with a decreased chance of smoking cessation. 
Conclusions: Cytisine therapy is not associated with an increase in adverse events in patients with CAD 
after PCI. Cytisine is tolerable but effective in short-term follow-up only when the treatment is completed. 
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Cardiovascular diseases are the most common cause 
of death among cigarette smokers [1]. Thus, smoking 
cessation, an effective lifestyle intervention [2], is crucial 
for primary and secondary prevention of coronary artery 
disease (CAD). Pharmacotherapy for smoking cessation 
significantly increases the rate of smoking cessation, but it is 
rarely implemented in clinical settings [3, 4]. First-line phar-
macotherapies with nicotine replacement therapy (NRT), 
varenicline or bupropion, are the recommended course of 
action for smoking cessation [5]. NRTs (gum, transdermal 
patch, nasal spray, inhaler, and sublingual tablets/lozenges) 
increase the probability of smoking cessation, with a risk 
ratio of 1.6, compared with placebo [6]. The hemodynamic 
effects of NRT, due to nicotine release, cause adverse effects 
such as hypertension; thereby, NRT is less preferred among 
patients with CAD. Varenicline, a partial agonist of the 
α4-ß2 nicotinic acetylcholine receptor (nAChR), increases 
two-fold the success rate of effective smoking cessation [7]. 
Moreover, patients with acute coronary syndromes (ACS) 
treated with varenicline show a 10% increase in smoking 
abstinence compared with placebo, without an increase 
in major adverse cardiovascular events [8]. Another partial 
agonist of the α4–ß2 nAChR, with a similar mechanism of 
action as varenicline, is cytisine, which is naturally derived 
from Cytisus laburnum and affects the reward pathway [9, 
10]. The treatment duration with cytisine (25 days) is sub-
stantially shorter than with varenicline (12 weeks) which 
may influence the lack of non-inferiority of cytisine vs varen-
icline in recent trial [11]. Nevertheless, cytisine is inexpensive 
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W H A T ’ S  N E W ?
Cytisine increases the success rates of smoking cessation in the general population. Due to lack of relevant data the drug was 
contraindicated in patients early after acute coronary syndromes (ACS) or unstable coronary artery disease, with special alert to 
patients with coronary artery disease (CAD). This is the first prospective study to assess the safety and short-term effectiveness 
of cytisine on smoking cessation in active smokers with CAD, who have undergone percutaneous coronary intervention (PCI). 
Our findings suggest that cytisine may be introduced in a wider group of patients with CAD.
and outperforms NRTs (odds ratio [OR] 1.5; 95% confidence 
interval [CI] 1.2–1.9; P = 0.003) for smoking cessation [7, 12]. 
Despite large randomized trials, cytisine is registered only 
in Europe and still not approved in the United States. Due 
to low cost and high accessibility, cytisine might be an op-
tion as a smoking cessation aid in secondary prevention in 
patients with CAD. However, to the best of our knowledge, 
there have been no published studies regarding cytisine 
use in patients with CAD after percutaneous coronary inter-
vention (PCI). Cytisine was registered for the approved indi-
cations, except for early ACS or unstable coronary disease, 
with a special alert to patients with CAD, owing to the lack 
of relevant data at the time of approval [13]. Furthermore, 
the registration was based on unpublished data from the 
1960s; the data did not include patients who underwent 
PCI. This data has not been updated since then, despite 
substantial progress in the interventional treatment of CAD. 
Furthermore, contraindications to cytisine in these groups 
of patients are not well documented and are based on a mild 
elevation in blood pressure, transient tachycardia, and 
blood glucose levels [9, 14–16]. These effects are driven by 
adrenergic stimulation and by neuronal and adrenal nAChR 
activation. Both cytisine and nicotine have a high affinity 
to the α4-β2 subtype, which is involved in the mechanism 
of action of nicotine [9, 14].
In the present study, we sought to evaluate the safety, 
feasibility, and efficacy of cytisine use for smoking cessa-
tion in active smokers with CAD within 30 days post PCI. 
We hypothesized that cytisine use will increase the rate of 




This was a nonrandomized prospective investigation of 
active smokers, following PCI. Patients with stable CAD 
and ACS admitted to the catheterization laboratory in the 
Department of Cardiology, Grochowski Hospital, Warsaw, 
Poland between 2015 and 2018 were screened for active 
smoking. The inclusion criteria for patients were as follows: 
28–32 days after PCI, aged 18 years or older, smoking at 
least 10 cigarettes a day, urine cotinine level of 6 based 
on the NicAlert test [17], and planning to quit smoking. 
The exclusion criteria were as follows: hypersensitivity to 
cytisine, clinically relevant heart rhythm disorder, uncon-
trolled hypertension, class III CAD according to Canadian 
Cardiovascular Society, the use of other agents for smok-
ing cessation and pregnancy. Medical history, nicotine 
dependence, and readiness for smoking cessation were 
determined at baseline. Patients were included based on 
the self-declaration to quit smoking; the readiness to quit 
smoking score was assessed. Adverse events, smoking 
activity based on the NicAlert test, and drug adherence 
were assessed at the follow-up visit 28–32 days after the 
baseline visit. Patients who did not attend the follow-up 
visit were contacted by telephone. 
Ethical considerations
This study complied with the Declaration of Helsinki and 
was approved by the ethics committee of the Centre 
of Postgraduate Medical Education (approval number 
16/PB/2014 and 10/PB-A/2015). The study was registered 
at ClinicalTrials.gov and the identifier NCT040784702 was 
assigned. All patients provided written informed consent 
for participation in the study. Patients were recruited in the 
Department of Cardiology of the Centre of Postgraduate 
Medical Education, Warsaw, Poland.
Smoking status
The Fagerström test and readiness to quit smoking score 
were used to assess nicotine dependence and motivation 
to quit smoking, respectively; these were performed at 
baseline. The Fagerström test is the most commonly used 
test to assess nicotine dependence. Levels 6 and above 
predict a high level of nicotine dependence and indi-
cate the need for a high level of behavioral support and 
pharmacological aid [18, 19]. The readiness to quit score, 
which assesses the motivation to quit smoking, consists 
of 12 questions, and it was locally developed for Polish 
patients. Levels 7 and above indicate a high motivation for 
smoking cessation [20]. Self-declaration of smoking status 
was verified by evaluating urine cotinine level at baseline 
and follow-up visits (30 days) using the Accutest NicAlert 
(Jant Pharmacal Corporation, Encino, CA, USA); a level of 0, 
1, or 2 indicated a urine cotinine level of ≤100 ng/ml and 
confirmed smoking cessation [17].
Interventions
All patients declared to willingly attempt to quit smoking. 
All patients were advised to stop smoking and received 
low-intensity counseling focused on the benefits of 
815
Bogumił Ramotowski, Andrzej Budaj, Cytisine in smoking patients with CAD after PCI
w w w . j o u r n a l s . v i a m e d i c a . p l / k a r d i o l o g i a _ p o l s k a
quitting, such as the reduced risk of CAD. Additionally, 
behavioral therapy was offered, which consisted of brief 
medical advice, psychological advice (<30 minutes), and 
being contacted twice during follow-up. Standard cytisine 
therapy (Desmoxan®; 1.5 mg tablet, a 25-day course) was 
offered to all patients, and cytisine therapy was started 
at the discretion of the patients. The study group consist-
ed of patients who consented to start cytisine therapy. 
Patients who denied cytisine therapy represented the 
control group.
Endpoints
The primary endpoint was the differences in adverse 
events between the study and the control group. The 
observed adverse events were as follows: gastrointestinal 
symptoms, including dry mouth, nausea, and abdominal 
pain; psychiatric symptoms, including anxiety, insomnia, 
and suicidal thoughts; cardiovascular symptoms, including 
chest pain, increased blood pressure (mean self-measured 
blood pressure ≥140/90 mm Hg, or single measurement 
≥180/110 mm Hg either self-measured or measured at 
clinical visit), and arrhythmia. Major adverse events ob-
served were myocardial infarction, stroke, hospitalization, 
and death from any cause.
The secondary endpoint was confirmed smoking ces-
sation using the NicAlert test at the follow-up visit.
Statistical methods
It was estimated to enroll 117 patients powered to have an 
80% chance of detecting a between-group difference of 
25% in smoking cessation using a P value of 0.05 with a 10% 
drop-out rate. Baseline characteristics were presented as 
mean and SD or median and interquartile range (IQR) for 
continuous data normally and non-normally distributed, 
respectively, and frequency for categorical data. A Shap-
iro-Wilk test was applied to assess for data normality. A t-test 
or Wilcoxon rank-sum test was used for between-group 
comparisons of continuous data. The Chi-squared or the 
Fisher exact test was used for between-group comparisons 
of categorical data. A multivariable logistic regression mod-
el was used to investigate the covariates associated with 
higher odds of smoking cessation. The following variables 
were included in the model: age, sex, body mass index, 
education, marital status, number of pack-years of smoking, 
previous attempts to stop smoking, passive smoking, the 
Fagerström index, readiness to quit score, the reason for 
PCI (CAD or ACS), and medical history. Relevant medical 
histories included: myocardial infarction, stroke, coronary 
artery bypass grafting, PCI, hypertension, hyperlipidemia, 
chronic obstructive pulmonary disease, peripheral artery 
disease, diabetes mellitus, renal failure, and rheumatoid 
arthritis. The backward selection at a level of 0.1 was imple-
mented to fit the model to identify factors at the 5% level of 
significance. ORs with 95% CI were calculated. All analyses 
were performed using the Stata 14.1 software (StataCorp 
LP, College Station, Texas, USA).
RESULTS
One hundred and seventeen active smokers with a level 
of 6 (NicAlert) were included in this study, 28–32 days 
post-PCI. Seventy-nine (67.5%) patients consented to use 
cytisine (study group) at the first visit (baseline) (Figure 1). 
The remaining 38 (32.5%) patients declined cytisine treat-
ment (control group). Among patients who declined to 
use cytisine 6 (15.8%) declared strong will to withdraw 
from smoking which according to the patient did not 
require pharmaceutical help, 4 (10.5%) clearly declared 
that they would not use cytisine due to cardiovascular 
contraindications mentioned in the product information, 
28 (73.7%) refused but did not provide a particular reason. 
Of the patients who consented to use cytisine at the first 
visit, only 64 started cytisine treatment; 15 patients did not 
start the treatment despite consenting. Of the 64 patients 
who started cytisine treatment, 32 completed the 25-day 
course. Ninety-one patients (64 from the study group and 
27 from the control group) completed the 30-day follow-up 
visit. Of these, 47 patients quit smoking; confirmed using 
the NicAlert test (levels from 0–2), and 44 patients did not 
quit smoking (levels ≥3). All patients from the study group 
who attended the follow-up visit had started cytisine 
therapy. Patients who did not attend the follow-up visit 
were contacted via telephone and requested to complete 
a questionnaire regarding smoking cessation, cytisine 
use, and adverse events. All patients who failed to attend 
the follow-up visit did not stop smoking and declared 
lack of motivation as the reason for not attending the 
follow-up visit.
The clinical characteristics of the patients enrolled in 
the trial are presented in Table 1. The mean (SD) age of 
patients was 60.8 (7.7) years; 67 (73.6%) patients were 
men, and 42 (46.15%) patients underwent PCI for ACS. 
The median and interquartile range (IQR) of the number 
of cigarettes smoked was 14.5 (10–20), and the pack-years 
was 40 (30–46.5). The mean of Fagerström and readiness to 
quit index indices were 4.8 ± 1.7 and 9.0 ± 1.6, respectively.
The clinical characteristics of the patients in the study 
group did not differ from the control group (Table 1). Nei-
ther the criterion for high nicotine addiction (Fagerström 
index ≥6) nor increased motivation for smoking cessation 
(readiness to quit score ≥7) differed between the groups 
at baseline.
The frequency of all adverse events was similar between 
the groups (14 [17.7%] vs 8 [21%]; P = 0.67). Additionally, 
the prevalence of particular adverse events did not differ 
between the groups (Table 2). Among all of the adverse 
events, the most common were gastrointestinal symptoms 
(10 [45%]; nausea, 5 [23%]; abdominal pain, 3 [14%]; and 
dry mouth, 2 [9%]). Other reported adverse events were 
increased anxiety, 5 (23%); insomnia, 2 (9%); atypical chest 
pain, 3 (14%); and increased blood pressure, 2 (9%). No 
major cardiovascular adverse events were reported at fol-
low-up. Thirty-two patients (40.5%) discontinued cytisine 
therapy. The most common reason for cytisine discontin-
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Figure 1. Flow chart of the study.
Abbreviations: PCI, percutaneous coronary intervention
Patients admitted to the catheterization 
laboratory for coronary angiography or PCI, 
between 2015 and 2018
(n = 3182)
Patients that declared active 
cigarette smoking after PCI
(n = 475)
— Patients who did not full 
the egibility criteria
— Lack of contact
Patients contacted 
(n = 195)
— Lack of consent
— Ineligibility for clinical visit
— Lack of visit (n = 73)
Visit 1 — patients who decalred 
active smoking
(n = 122) — Smoking cessation between 
contact and visit 1 (n = 2)
— NicAlert < 6 despite 
declaration of smoking (10 
cigarettes daily) (n = 2)
— Other (n = 1)
Patients enrolled in the trial
(n = 117)
Study group — 79 patients 
who consented to use cytisine
Control group — 38 patients 
who declined cytisine use
Table 1. Patient demographics and clinical characteristics
Variables Baseline visit (n = 117)
Study group




 (study vs control group)









Males, n (%) 67 (57.2) 61 (77.2) 25 (66) 0.19
BMI, kg/m2, mean (SD) 27.9 (4.4) 28 (4.2) 28.1 (4.9) 0.91
Indications for PCI ACS, n (%) 55 (47) 33 (41.8) 22 (57.9) 0.102
Diabetes, n (%) 29 (24.8) 19 (24) 10 (26.3) 0.79
Hypertension, n (%) 94 (80.3) 63 (79.75) 30 (78.95) 0.92
History of MI, n (%) 30 (25.6) 20 (25.3) 10 (26.3) 0.908
Hyperlipidemia, n (%) 84 (71.8) 53 (67) 31 (81.6) 0.103
History of renal failure, n (%) 7 (5.9) 5 (6.3) 2 (5.2) 1.0
COPD, n (%) 8 (6.8) 6 (7.6) 2 (5.2) 1.0
Data on smoking number of cigarettes smoked, median (IQR) 14.5 (10–20) 12 (10–20) 15 (10–20) 0.54
Habit of smoking, years, median (IQR) 40 (32.5–45) 40 (33–45) 40 (30–43) 0.32
Pack-years, median (IQR) 40 (30–46.5) 40 (30–47) 39 (27–36) 0.46
Fagerström questionnaire, mean (SD) 
Index ≥6; n (%)






Readiness to quit test, mean (SD)
Index ≥7; n (%)






Abbreviations: ACS, acute coronary syndrome; BMI, body mass index; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; MI, myocardial infarction; PCI, 
percutaneous coronary intervention; SD, standard deviation
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uation was a perceived lack of effectiveness (19 [59.3%]). 
Thirteen patients (20.3%) who started cytisine therapy 
discontinued treatment due to adverse events.
The study and control groups had similar success rates 
of smoking cessation in an intention-to-treat analysis 
(33 [41.8%] vs 14 [36.8%]; P = 0.61). An analysis of patients 
who completed cytisine therapy revealed that only the 
patients who completed cytisine therapy significantly 
succeeded in smoking cessation compared with those not 
treated with cytisine, or those who did not complete cytis-
ine therapy (Table 3) (complete therapy: 69.7%; not treated: 
36.8%; incomplete therapy, 25%; P <0.001). According to 
the multivariable logistic regression analysis, completion of 
cytisine therapy (OR: 5.79; 95% CI: 1.99–16.86) and ACS at 
admission (OR: 3.2; 95% CI: 1.05–9.78) were associated with 
an increased success rate of smoking cessation, whereas 
decreased smoking cessation was observed with male sex 
(OR: 0.21; 95% CI: 0.06–0.68) (Table 4).
DISCUSSION
To the best of our knowledge, this is the first prospective 
study to assess the safety and effect of cytisine on smoking 
cessation in active smokers with CAD previously treated 
with PCI. Our results revealed that cytisine use in this group 
of patients was not associated with an increased risk of ad-
verse events. However, a substantial proportion of patients 
did not start cytisine therapy despite obtaining the drug, 
and a substantial proportion of patients did not complete 
the therapy. Noteworthy, only a complete course of cytisine 
was associated with a higher rate of smoking cessation. 
To our knowledge, there have been no previous reports 
on cytisine treatment in patients with CAD and the safety 
of this drug in the early period post-PCI, especially in pa-
tients with ACS. A meta-analysis on NRT proved a higher 
incidence of symptoms related to sympathomimetic effects 
of nicotine such as tachycardia and arrhythmia, without an 
increase in major adverse cardiovascular events [21]. Cytis-
ine is a partial nicotine agonist; therefore, it may cause sim-
ilar symptoms [9, 14–16]. In this trial, only a small number 
of patients reported atypical chest pain or elevated blood 
pressure, which might be attributable to nAChR activation; 
we did not observe any events of tachycardia or arrhythmia. 
In patients with stable CAD treated with varenicline, the 
rate of cardiovascular events was comparable to placebo 
[22]. Among these patients, the most commonly reported 
symptoms were nausea, vomiting, insomnia, and abnormal 
dreams [22]. The most common adverse events in our study 
were gastrointestinal symptoms such as nausea, and this 
is consistent with the findings of previous studies with 
cytisine [23]. We did not record any major adverse events 
such as serious cardiovascular events. 
In our trial, patients were recruited 30 days after PCI. 
Due to the lack of published data on cytisine use, a 30-day 
waiting period following PCI was chosen to avoid the peri-
od of the highest risk of cardiovascular adverse events and 
major fluctuations in platelet reactivity [24, 25].
In the largest randomized study on cytisine published 
to date, West et al. [26] reported a smoking cessation rate 
of 8.4% (vs 2.4%) during 12 months of observation, and 
abstinence was verified by assessing the concentration 
of carbon monoxide. However, patients with a previous 
diagnosis of severe atherosclerotic disease and who had 
undergone PCI were excluded from the latter study. In our 
study, we found relatively high rates of smoking cessation 
(69.7% in the complete cytisine therapy group, 36.8% in 
the no therapy group, and 25% in the incomplete therapy 
group). The high rate of cessation may be owing to the 
preselection of patients with established CAD treated 
with PCI, short observation period, or the high level of 
counseling. On the other hand, the rate of cytisine discon-
tinuation in our trial was 40.5%, whereas the previously 
reported rate of varenicline discontinuation was 9.6% [22]. 
The most common reason for discontinuation in our trial 
was perceived lack of effectiveness. Increased attendance 
of follow-up and more frequent contact with patients 
scheduled to undergo cytisine therapy might be requested 
to reduce the risk of discontinuation. 
Table 2. Frequency of adverse events





Nausea, n (%) 4 (5) 1 (2.6) 1.0
Abdominal pain, n (%) 1 (1.3) 0 (0) 1.0
Dry mouth, n (%) 2 (2.5) 0 (0) 1.0
Anxiety, n (%) 2 (2.5) 3 (7.9) 0.327
Insomnia, n (%) 2 (2.5) 0 (0) 1.0
Atypical chest pain, n (%) 3 (3.8) 2 (5.3) 0.639
Increase in blood pressure, n (%) 1 (1.3) 1 (2.6) 0.546
Table 3. Success rates in smoking cessation concerning complete 
cytisine therapy
Groups Frequency P-value
Complete cytisine therapy vs 
incomplete therapy, n (%)
23 (69.7) vs 24 (34.8) 0.001
Complete cytisine therapy vs 
no therapy, n (%)
23 (69.7) vs 14 (36.8) 0.006
Incomplete cytisine therapy vs 
no therapy, n (%)
10 (25) vs 14 (36.8) 0.257
Table 4. Factors influencing the success in smoking cessation at 
follow-up visit — multivariable regression analysis
Variables OR (95% CI) P-value
Complete cytisine therapy 
(complete vs others)
5.79 (1.99–16.86) 0.001






Abbreviations: ACS, acute coronary syndrome; CI, confidence interval; OR, odds 
ratio
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In this study, we excluded patients treated with NRT 
because their smoking status could not be confirmed with 
the urine cotinine test. Moreover, cytisine was found to be 
superior to NRT therapy in a large randomized trial [12].
Although West et al. [26] verified smoking cessation by 
evaluating the concentrations of carbon monoxide, we as-
sessed urine cotinine levels; it is considered to be a stronger 
indicator of smoking cessation over 48–72 hours [27].
The pharmacodynamics of cytisine is a matter of con-
cern because it does not cross the blood-brain barrier. 
Additionally, there is no information on serious adverse 
events in patients with mood disorders and other addic-
tions. Varenicline is a synthetic drug that binds to the same 
α4-β2 nAChR as cytisine and crosses the blood-brain barrier 
with a marked effect on the receptors [28]. Furthermore, in 
2009, the Food and Drug Administration released a black 
box warning against varenicline, associating the drug to 
mental health disorders [29], although further studies did 
not support its detrimental effect on mood disorders [30, 
31]. Nevertheless, varenicline use was related to a higher 
risk of sleep disorders or anxiety syndromes [22]. In our 
study, patients treated with cytisine rarely reported in-
creased anxiety or insomnia in both groups.
Our study has a few limitations. First, the study was not 
randomized and did not include a placebo control group. 
Second, cytisine intake was at the discretion of the patients, 
and this may have led to an entry of bias. Third, some pa-
tients were lost to follow-up visits, especially from the con-
trol group (29%). However, such patients were contacted 
via phone, and none of them declared smoking cessation. 
Fourth, patients were followed up only for a short term of 
30 days, nevertheless, the follow-up did include cotinine 
assessment as an objective biomarker. Finally, the small 
sample size limits our findings. Despite these limitations, 
our study provides important data regarding cytisine use 
in smoking patients with CAD. Our findings suggest that 
cytisine use may not be contraindicated in CAD patients 
including the ACS group 30 days after PCI. To increase 
compliance, patients undergoing cytisine therapy should 
be regularly contacted and supported.
CONCLUSIONS
Cytisine is a safe and promising drug for the treatment of 
patients with CAD initiated 30 days after PCI. However, the 
compliance of the patients is low, including patients who 
do not start and do not complete the treatment. Owing to 
the low cost, cytisine therapy may be beneficial for smoking 
cessation in a wide group of patients with CAD. Further 
research is required to confirm its efficacy and safety.
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